P2D Bioscience has received a $320,000 federal grant to develop a novel class of anti-inflammatory drugs that target lung disease.
Specifically, the to-be-developed drugs will be aimed at treating acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease (COPD) and asthma.
The first phase of work will assess the validity of the drugs’ targets, while the next phase will focus on the safety and pharmacokinetics of the lead drug candidates.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The grant to Cincinnati-based P2D comes from the U.S. National Heart, Lung and Blood Institute, according to a statement from the company.
P2D will work with researchers from Cincinnati Children’s Hospital Medical Center to develop the drugs.
The last month has been a lucrative one in attracting federal grants for P2D. In June, the company received a $1.5 million federal grant to develop a drug for attention-deficit/hyperactivity disorder.
